Light-adjustable lens continues to impress

Article

Early experience from a pilot study shows that spherocylindrical error after cataract surgery can be corrected with a proprietary light-adjustable lens (LAL; Calhoun Vision) to improve uncorrected visual acuity (UCVA), said Arturo S. Chayet, MD.

Early experience from a pilot study shows that spherocylindrical error after cataract surgery can be corrected with a proprietary light-adjustable lens (LAL; Calhoun Vision) to improve uncorrected visual acuity (UCVA), said Arturo S. Chayet, MD.

Dr Chayet, medical director, Codet Laser Vision Institute, Tijuana, Mexico, presented results from the first six patients who underwent small-incision surgery and implantation of the lens followed by treatment for residual spherocylindrical error. All patients had at least two to three weeks of post-adjustment follow-up.

Mean cylinder prior to adjustment was –1.37 D and it was reduced to a mean of –0.50 D. The mean vectorial cylinder adjustment was –0.87 D.

Post-adjustment UCVA was improved compared with the pre-adjustment level in all eyes and was 20/25 or better. No eyes lost BCVA. Topographic evaluations showed no change in the corneal maps while wavefront aberrometry illustrated the reduction of astigmatism.

"There are many potential advantages of toric adjustment with the [lens]," Dr Chayet said. "It offers a precise method for correcting sphere and cylinder while allowing surgeons to maintain their same technique with respect to incision location and IOL placement. In addition, the spatial profile of it can be written along with multifocal corrections.

"With available technology, it is possible to correct up to 2.5 D of cylinder at the spectacle plane," he concluded. "The next step will be to refine the nomograms to achieve higher levels of correction."

 

Read

ASCRS 2008 meeting highlights.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.